Results 41 to 50 of about 796 (164)

Real‐world effectiveness of highly purified cannabidiol in epilepsy associated with 15q11.2‐q13.1 duplication and deletion syndromes: A multicenter study

Epilepsia Open, Volume 11, Issue 3, Page 1046-1053, June 2026.
Abstract This multicenter retrospective study evaluated the effectiveness and safety of highly purified cannabidiol (CBD) in 22 patients with 15q11.2‐q13.1 duplication or deletion syndromes (15q‐DDS), including 12 with 15q duplication syndrome (dup15q) and 10 with Angelman syndrome (AS). Median (interquartile range [IQR]) age at CBD initiation was 14.5
Emanuele Cerulli Irelli, Adolfo Mazzeo, Marco Perulli, Georgia Ramantani, Domenica Battaglia, Irene Bagnasco, Erica Cognolato, Pasquale Striano, Susanna Negrin, Alberto Danieli, Paolo Bonanni, Francesca F. Operto, Carlo Di Bonaventura, Antonietta Coppola, Alessandro Orsini   +14 more
wiley   +1 more source

Table2_Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database.XLS

Objective:This study aims to analyze adverse drug events (ADEs) associated with cenobamate from the FAERS database, covering the third quarter of 2020 to the second quarter of 2023.Methods:Data related to cenobamate-associated ADEs from the third quarter
Huiqin Xu (1459831), Wenqiang Fang (16558371), Linqian Zhao (18158284), Shihao Chen (304374)   +3 more
core   +1 more source

Cenobamate’s effect on mood and seizure frequency

Epilepsy & Behavior
Real-world experience with efficacy and tolerability of newly approved antiseizure medications (ASM) often diverges from findings in their controlled clinical trials. Cenobamate (CNB), demonstrated a high responder rate and seizure freedom in placebo-controlled trials.
Mert Karatas, Alperan Yavuz, Blake Newman, Angela Peters, Brian Johnson, Sindhu Richards, Pawan Rawal, Adrian Rothenfluh, Amir Arain   +8 more
openaire   +2 more sources

Table1_Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database.XLS

Objective:This study aims to analyze adverse drug events (ADEs) associated with cenobamate from the FAERS database, covering the third quarter of 2020 to the second quarter of 2023.Methods:Data related to cenobamate-associated ADEs from the third quarter
Huiqin Xu (1459831), Wenqiang Fang (16558371), Linqian Zhao (18158284), Shihao Chen (304374)   +3 more
core   +1 more source

Potential of cenobamate as a broad-spectrum antiseizure medication

Expert Opinion on Pharmacotherapy
The process of diagnosing patients with epilepsy and selecting the optimal drug remains a significant challenge. Broad-spectrum antiseizure medications (ASMs) treat focal and generalized seizures without worsening other seizure types, making them the drug of choice when the exact seizure classification for patients is unknown.
Susan M, Melnick, Sunita N, Misra, Marc, Kamin, Louis, Ferrari, Kelli J, Glenn   +4 more
openaire   +2 more sources

Cenobamate, a New Promising Antiseizure Medication: Experimental and Clinical Aspects

About 40–50% of patients with drug-resistant epilepsy do not properly respond to pharmacological therapy with antiseizure medications (ASMs). Recently approved by the US Food and Drug Administration and European Medicines Agency as an add-on drug ...
Barbara Błaszczyk, Stanisław J. Czuczwar, Barbara Miziak   +2 more
core   +1 more source

Cenobamate in adult patients with epilepsy and intellectual disability

Seizure: European Journal of Epilepsy
In people with intellectual disability (ID), prevalence of epilepsy is up to 50-times higher than in the general population and often difficult to treat. Multiple randomized controlled, observational and retrospective studies have demonstrated favorable efficacy of adjunctive cenobamate (CNB).
David Steinbart, Rebekka Geelhaar, Rebekka Lehmann, Anja Grimmer, Martin Holtkamp   +4 more
openaire   +2 more sources

Molecular and vibrational structure of Cenobamate investigated by MD and DFT

LAUREA MAGISTRALEIl Cenobamate (CNB) è un farmaco antiepilettico comunemente utilizzato insieme ad al- tri farmaci anticonvulsivanti in una terapia combinata, che può essere gestita in modo ottimale tramite l’applicazione di Therapeutic Drug ...
BENEDETTO, FABIO
core  

Budget impact analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands

ObjectiveThe objective of this study was to explore the financial consequences of adopting cenobamate as a treatment alternative in epilepsy patients with drug-resistant focal onset seizures (FOS) from a societal perspective in the Netherlands.MethodsA ...
Rijkers, Kim, Evers, Silvia; id_orcid, Lazeron, Richard, Klarenbeek, Pim, Laskier-Owens, Vicki, Hiligsmann, Mickael, Rouhl, Rob, Li, Nannan, Majoie, Marian, Gubler, Felix   +9 more
core   +1 more source

Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands

OBJECTIVE: To assess the cost-effectiveness of cenobamate in epileptic people with focal seizures in the Netherlands. METHODS: A Markov model was used to simulate lifetime costs and quality-adjusted life years (QALYs) for cenobamate compared to ...
Rijkers, Kim, Evers, Silvia; id_orcid, Lazeron, Richard, Hiligsmann, Mickaël, Klarenbeek, Pim, Laskier-Owens, Vicki, Rouhl, Rob, Li, Nannan, Majoie, Marian, Gubler, Felix   +9 more
core   +1 more source